Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 2067-2075

  Wong, W W L ^a   Tan, M M ^a   Xia, Z ^a   Dimitroulakos, J ^a   Minden, M D ^a   Penn, L Z ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PYROPHOSPHATE; STATINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

ACUTE DISEASE; APOPTOSIS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; LOVASTATIN; NEOPLASMS; PYRIDINES; PYRROLES; SENSITIVITY AND SPECIFICITY; TUMOR CELLS, CULTURED;

EID: 0034777844     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Regulation of the mevalonate pathway
2. Current and future treatment of hyperlipidemia: The role of statins
3. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
4. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study
5. Pharmacology of competitive inhibitors of HMG-CoA reductase
6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences
7. Selective inhibition of primary acute myeloid leukemia cell growth by simvastatin
8. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukemic and normal bone marrow progenitors
9. Autocrine and paracrine growth control by granulocyte-monocyte colony- stimulating factor of acute lymphoblastic leukemia cells
10. Blocking protein geranylgeranylation is essential for apoptosis of human acute myeloid leukemia cells triggered by lovastatin
11. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
12. Features of apoptotic cells measured by flow cytometry
13. Cytokine-induced selective expansion and maturation of erythroid versus myeloid progenitors from purified cord blood precursor cells
14. Self-renewal of primitive human hematopoietic cells (longterm culture-initiating cells) in vitro and their expansion in defined medium
15. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
16. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice
17. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia
18. Lovastatin-induced apoptosis in prostate stromal cells
19. Lovastatin induces apoptosis in malignant mesothelioma cells
20. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
21. Lovastatin-induced proliferation inhibition and apoptosis in C6 glial cells
22. Differential tumor cell sensitivity to lovastatin induced apoptosis: Therapeutic implication
23. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia
24. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: The pivotal placebo-controlled clinical trial
25. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: A multicentre, randomized, double-blind, placebocontrolled study
26. Preclinical review of cerivastatin sodium-a step forward in HMG-CoA reductase inhibition
27. Cerivastatin in primary hyperlipidemia-a multicenter analysis of efficacy and safety
28. Biopharmaceutical profile of cerivastatin: A novel HMG-CoA reductase inhibitor
29. Clinical pharmacokinetics of cerivastatin
30. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
31. Cerivastatin: Pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
32. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin
33. Influence of cholestyramine on the pharmacokinetics of cerivastatin
34. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
35. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMGCoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers
36. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice